[HTML] sciencedirect.comFull View

[HTML][HTML] Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel

SL Close, SJ Iturria, CD Payne, NA Farid… - Journal of Thrombosis …, 2007 - Elsevier
Background: Thienopyridines are metabolized to active metabolites that irreversibly inhibit
the platelet P2Y 12 adenosine diphosphate receptor. The pharmacodynamic response to …
被引用次数：957 相关文章

Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel

JT BRANDT, SL CLOSE, SJ ITURRIA… - … of Thrombosis and …, 2007 - Wiley Online Library
Background: Thienopyridines are metabolized to active metabolites that irreversibly inhibit
the platelet P2Y12 adenosine diphosphate receptor. The pharmacodynamic response to …

Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel

JT BRANDT, SL CLOSE, SJ ITURRIA… - Journal of Thrombosis …, 2007 - jthjournal.org
Background: Thienopyridines are metabolized to active metabolites that irreversibly inhibit
the platelet P2Y 12 adenosine diphosphate receptor. The pharmacodynamic response to …

Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel.

JT Brandt, SL Close, SJ Iturria, CD Payne… - … of Thrombosis and …, 2007 - europepmc.org
Background Thienopyridines are metabolized to active metabolites that irreversibly inhibit
the platelet P2Y (12) adenosine diphosphate receptor. The pharmacodynamic response to …

Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel

JT Brandt, SL Close, SJ Iturria… - … of thrombosis and …, 2007 - pubmed.ncbi.nlm.nih.gov
Background Thienopyridines are metabolized to active metabolites that irreversibly inhibit
the platelet P2Y (12) adenosine diphosphate receptor. The pharmacodynamic response to …
[PDF] academia.edu

[PDF][PDF] Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel

JT BRANDT, SL CLOSE, SJ ITURRIA… - Journal of Thrombosis …, 2007 - academia.edu
Background: Thienopyridines are metabolized to active metabolites that irreversibly inhibit
the platelet P2Y12 adenosine diphosphate receptor. The pharmacodynamic response to …

[引用][C] Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel

J BRANDT - J Thromb Haemost, 2007 - cir.nii.ac.jp
Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and
pharmacodynamic response to clopidogrel but not prasugrel | CiNii Research CiNii 国立情報学 …
[PDF] academia.edu

[PDF][PDF] Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel

JT BRANDT, SL CLOSE, SJ ITURRIA… - Journal of Thrombosis …, 2007 - academia.edu
Background: Thienopyridines are metabolized to active metabolites that irreversibly inhibit
the platelet P2Y12 adenosine diphosphate receptor. The pharmacodynamic response to …

[引用][C] Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel

B JT - J Thromb Haemost., 2007 - cir.nii.ac.jp
Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and
pharmacodynamic response to clopidogrel but not prasugrel | CiNii Research CiNii 国立 …